Frontiers in Digestive Diseases Symposium
“Metabolic Communication in Digestive Diseases”
Saturday, March 4, 2023 | 8:00 am – 3:00pm | Baylor St. Luke’s Medical Center | 7200 Cambridge

Join us as we discuss new developments in the area of metabolic research and metabolic communication in digestive diseases. During this conference, the expert speakers will talk on gut and microbial metabolites that influence metabolism, liver pathophysiology and metabolic disorders.

"Gut microbial drivers of host metabolism: Implications for Health and Disease"
Eugene B. Chang, M.D., Martin Boyer Professor of Medicine
University of Chicago, USA, Chicago, IL

"Intestinal fructose metabolism and metabolic disease"
Mark A. Herman, M.D., Section Chief, Endocrinology, Diabetes, and Metabolism
Baylor College of Medicine, USA, Houston, TX

"Lipid dysregulation of immune responses to intestinal injury"
Andrea McAlester, Ph.D., Instructor, Pathology & Immunology, 2021 DDC Pilot Feasibility Awardee
Baylor College of Medicine, USA, Houston, TX

“Regulation of the host-microbiota relationship”
Theresa Alenghat, VMD, Ph.D., Associate Professor, Pediatrics
Cincinnati Children’s Hospital, USA, Cincinnati, OH

“Gut microbiome based personalized medicine in NAFLD”
Rohit Loomba, M.D., MHSc, Vice Chair, Gastroenterology, Director & Professor, Hepatology
University of California San Diego, USA, San Diego, CA

“Circadian nuclear contenders in NASH and hepatocellular carcinoma”
Kristin Eckel-Mahan, Ph.D., Associate Professor, Center for Metabolic and Degenerative Diseases
The University of Texas Health Science Center, USA, Houston, Tx

“Bariatric surgery as an integrative physiology approach to obesity treatment”
Darleen Sandoval, Ph.D., Professor of Pediatrics and Medicine
University of Colorado, Anschutz Medical Campus, USA, Aurora, CO

TARGET AUDIENCE: Physicians, fellows, residents, medical students, advanced practice providers, nurses, and other healthcare providers.

EDUCATIONAL OBJECTIVES: At the conclusion of this live activity, participants should be better able to:
- Define metabolic communication in digestive diseases, its history and future applications
- Apply best practices and treatments for digestive diseases through metabolic communication.
- Identify opportunities to apply this knowledge to the detection and treatment of digestive diseases.
- Interpret the current metabolic research concerning GI infection and injury.

ACCREDITATION/CREDIT DESIGNATION: Texas Children’s Hospital is accredited by the Texas Medical Association to provide continuing medical education for physicians. Texas Children’s Hospital designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE: The speakers for this activity have reported no relevant financial relationships with any ineligible companies unless otherwise stated here: Mark A. Herman, MD – Receives Research Support from Eli Lilly and Company; Darleen Sandoval, PhD – Serves as a Consultant with Metis Therapeutics; Rohit Loomba, M.D., MHSc - Serves as a consultant to Aardvark Therapeutics, Alimmune, Amgen, Anylam/Regeneron, Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, CohBar, Eli Lilly, Galmed Pharmaceuticals, Gilead, Glympse Bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Metacrine Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Sagimet, Terns Pharmaceuticals, Theratechnologies, and Viking Therapeutics and receives Research grants were received from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Hanmi Pharmaceutical, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals and co-funder of LipoNexus (pending CME Committee member review). These relevant financial relationships have been appropriately mitigated. Persons involved in the planning of this activity have reported no relevant financial relationships with any commercial interest.

PLANNING COMMITTEE DISCLOSURE: The members of the Planning Committee and others involved in the planning of this activity have reported no relevant financial relationships with any ineligible companies.

CONFERENCE SUPPORT: This CME activity is supported by Silvio O Conte Digestive Diseases Research Core Center (NIH P30DK056338).

CONTACT INFORMATION: Sara Tristan, DDC Administrator, Department of Medicine, Gastroenterology, Baylor College of Medicine, 7200 Cambridge, A8.136, Houston, Texas 77030, escamill@bcm.edu, (713) 798-3478.